Myeloma light chains are ligands for cubilin (gp280).
Batumano(, Vecihi, Pierre J. Verroust#, Gabriel L. Navaro, James H.
Kayseno, Fatime O. Godao(, Eric Simono, Francoise Pontillon#,
Michelle Lyles@, Joanne Bruno@ and Timothy G. Hammondo(.
Department of Medicine/Section of Nephrology, oTulane University
School of Medicine, Tulane Environmental Astrobiology Center &(Tulane
Cancer Center, Veteran's Affairs Medical Center, New Orleans LA,
#Unite de Recherch[acute]es de Nephrologie Normale and Pathologique,
INSERM U.64 Hopital Tenon Paris CEDEX 20 France and @Pharmacia USA
Inc., Piscataway, NJ.
APStracts 5:0097F, 1998.
Although myeloma light chains are known to undergo receptor-mediated
endocytosis in the kidney, the molecular identity of the receptor has
not been characterized. We examined the interaction between cubilin
(gp280) and four species of light chains isolated from the urine of
patients with multiple myeloma. Four lines of evidence identify
cubilin, a giant glycoprotein receptor which is restricted in
distribution to endocytic scavenger pathways, and which has potent
effects on endosomal trafficking, as a potentially physiologically
relevant binding site for light chains:
Received 3 November 1997; accepted in final form 7 May 1998.
APS Manuscript Number F348-7.
Article publication pending Am. J. Physiol. (Renal Physiology).
ISSN 1080-4757 Copyright 1998 The American Physiological Society.
Published in APStracts on 16 June 1998